FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
BMC biotechnology2008; 8; 66; doi: 10.1186/1472-6750-8-66

Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV).

Abstract: Venezuelan equine encephalitis virus (VEEV) belongs to the Alphavirus group. Several species of this family are also pathogenic to humans and are recognized as potential agents of biological warfare and terrorism. The objective of this work was the generation of recombinant antibodies for the detection of VEEV after a potential bioterrorism assault or an natural outbreak of VEEV. Results: In this work, human anti-VEEV single chain Fragments variable (scFv) were isolated for the first time from a human naïve antibody gene library using optimized selection processes. In total eleven different scFvs were identified and their immunological specificity was assessed. The specific detection of the VEEV strains TC83, H12/93 and 230 by the selected antibody fragments was proved. Active as well as formalin inactivated virus particles were recognized by the selected antibody fragments which could be also used for Western blot analysis of VEEV proteins and immunohistochemistry of VEEV infected cells. The anti-VEEV scFv phage clones did not show any cross-reactivity with Alphavirus species of the Western equine encephalitis virus (WEEV) and Eastern equine encephalitis virus (EEEV) antigenic complex, nor did they react with Chikungunya virus (CHIKV), if they were used as detection reagent. Conclusions: For the first time, this study describes the selection of antibodies against a human pathogenic virus from a human naïve scFv antibody gene library using complete, active virus particles as antigen. The broad and sensitive applicability of scFv-presenting phage for the immunological detection and diagnosis of Alphavirus species was demonstrated. The selected antibody fragments will improve the fast identification of VEEV in case of a biological warfare or terroristic attack or a natural outbreak.
Get Full Text
Publication Date: 2008-09-02 PubMed ID: 18764933PubMed Central: PMC2543005DOI: 10.1186/1472-6750-8-66Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research work focuses on developing human antibody fragments to detect and diagnose Venezuelan equine encephalitis virus (VEEV), which poses a significant threat in bio-warfare and terrorism. These fragments, known as single chain Fragments variable (scFv) were generated from a human naïve antibody gene library and were specifically used to detect both active and inactive particles of various VEEV strains, demonstrating their potential in prompt identification of VEEV in bio-warfare, terrorism, or natural outbreaks.

Development of Human Antibody Fragments

  • The research was geared towards developing recombinant antibodies to detect the Venezuelan equine encephalitis virus (VEEV) which is classified under the Alphavirus species.
  • The researchers generated single chain Fragments variable (scFv), a type of human antibody fragment, from a human naïve antibody gene library using optimized selection processes.
  • Overall, eleven different scFv were created and evaluated for their immunological specificity.

Results: Specific Detection of VEEV Strains

  • The developed antibody fragments were proven to specifically detect VEEV strains TC83, H12/93, and 230.
  • The scFv could identify both active and formalin inactivated virus particles. This characteristic makes them valuable in various diagnostic procedures, including Western blot analysis of VEEV proteins and immunohistochemistry of VEEV-infected cells.

Testing Cross-Reactivity of the Anti-VEEV ScFv

  • The researchers tested the anti-VEEV scFv phage clones for potential cross-reactivity with other Alphavirus species and Chikungunya virus (CHIKV). The results were negative, indicating that there was no cross-reactivity observed.

Conclusions and Potential Applications

  • The study succeeded in producing, for the first time, antibodies against a human pathogenic virus from a human naïve scFv antibody gene library using complete, active virus particles as an antigen.
  • The study proved the broad and sensitive utility of scFv-presenting phage in immunological detection and diagnosis of Alphavirus species.
  • The developed scFv antibody fragments have potential to vastly improve the speed of VEEV identification in scenarios such as biological warfare, terroristic attacks, or natural outbreaks.

Cite This Article

APA
Kirsch MI, Hülseweh B, Nacke C, Rülker T, Schirrmann T, Marschall HJ, Hust M, Dübel S. (2008). Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol, 8, 66. https://doi.org/10.1186/1472-6750-8-66

Publication

BMC biotechnology
ISSN: 1472-6750
NlmUniqueID: 101088663
Country: England
Language: English
Volume: 8
Pages: 66

Researcher Affiliations

Kirsch, Martina Inga
  • Abteilung Biotechnologie, Institut für Biochemie und Biotechnologie, Technische Universität Braunschweig, Spielmannstrabetae 7, 38106, Braunschweig, Germany. martina.kirsch@tu-bs.de
Hülseweh, Birgit
    Nacke, Christoph
      Rülker, Torsten
        Schirrmann, Thomas
          Marschall, Hans-Jürgen
            Hust, Michael
              Dübel, Stefan

                MeSH Terms

                • Biological Assay / methods
                • Biosensing Techniques / methods
                • Encephalitis Virus, Venezuelan Equine / immunology
                • Encephalitis Virus, Venezuelan Equine / isolation & purification
                • Humans
                • Immunoassay / methods
                • Immunoglobulin Fragments / analysis
                • Immunoglobulin Fragments / immunology
                • Peptide Library

                References

                This article includes 57 references
                1. Kubes V, Ríos FA. THE CAUSATIVE AGENT OF INFECTIOUS EQUINE ENCEPHALOMYELITIS IN VENEZUELA.. Science 1939 Jul 7;90(2323):20-1.
                  pubmed: 17818578doi: 10.1126/science.90.2323.20google scholar: lookup
                2. Powers AM, Brault AC, Shirako Y, Strauss EG, Kang W, Strauss JH, Weaver SC. Evolutionary relationships and systematics of the alphaviruses.. J Virol 2001 Nov;75(21):10118-31.
                  pmc: PMC114586pubmed: 11581380doi: 10.1128/jvi.75.21.10118-10131.2001google scholar: lookup
                3. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication, and evolution.. Microbiol Rev 1994 Sep;58(3):491-562.
                  pmc: PMC372977pubmed: 7968923doi: 10.1128/mr.58.3.491-562.1994google scholar: lookup
                4. Johnson KM, Martin DH. Venezuelan equine encephalitis. 1974. pp. 79–116.
                5. Hawley RJ, Eitzen EM Jr. Biological weapons--a primer for microbiologists.. Annu Rev Microbiol 2001;55:235-53.
                  pubmed: 11544355doi: 10.1146/annurev.micro.55.1.235google scholar: lookup
                6. Powers AM, Oberste MS, Brault AC, Rico-Hesse R, Schmura SM, Smith JF, Kang W, Sweeney WP, Weaver SC. Repeated emergence of epidemic/epizootic Venezuelan equine encephalitis from a single genotype of enzootic subtype ID virus.. J Virol 1997 Sep;71(9):6697-705.
                  pmc: PMC191949pubmed: 9261393doi: 10.1128/jvi.71.9.6697-6705.1997google scholar: lookup
                7. Weaver SC, Salas R, Rico-Hesse R, Ludwig GV, Oberste MS, Boshell J, Tesh RB. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group.. Lancet 1996 Aug 17;348(9025):436-40.
                  pubmed: 8709783doi: 10.1016/s0140-6736(96)02275-1google scholar: lookup
                8. Sanchez JL, Takafuji ET, Lednar WM, LeDuc JW, Macasaet FF, Mangiafico JA, Rosato RR, Driggers DP, Haecker JC. Venezuelan equine encephalomyelitis: report of an outbreak associated with jungle exposure.. Mil Med 1984 Nov;149(11):618-21.
                  pubmed: 6438552
                9. Sudia WD, Newhouse VF, Beadle ID, Miller DL, Johnston JG Jr, Young R, Calisher CH, Maness K. Epidemic Venezuelan equine encephalitis in North America in 1971: vector studies.. Am J Epidemiol 1975 Jan;101(1):17-35.
                  pubmed: 235212doi: 10.1093/oxfordjournals.aje.a112068google scholar: lookup
                10. Franck P. Venezuelan Encephalitis. Pan American Health Organization Vol. 243. Washington DC; 1972. Round table on epidemic control; pp. 400–401.
                11. Rivas F, Diaz LA, Cardenas VM, Daza E, Bruzon L, Alcala A, De la Hoz O, Caceres FM, Aristizabal G, Martinez JW, Revelo D, De la Hoz F, Boshell J, Camacho T, Calderon L, Olano VA, Villarreal LI, Roselli D, Alvarez G, Ludwig G, Tsai T. Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995.. J Infect Dis 1997 Apr;175(4):828-32.
                  pubmed: 9086137doi: 10.1086/513978google scholar: lookup
                12. Leitenberg M. Biological weapons in the twentieth century: a review and analysis.. Crit Rev Microbiol 2001;27(4):267-320.
                  pubmed: 11791799doi: 10.1080/20014091096774google scholar: lookup
                13. Hoke CH Jr. History of U.S. military contributions to the study of viral encephalitis.. Mil Med 2005 Apr;170(4 Suppl):92-105.
                  pubmed: 15916288doi: 10.7205/milmed.170.4s.92google scholar: lookup
                14. Reed DS, Lind CM, Sullivan LJ, Pratt WD, Parker MD. Aerosol infection of cynomolgus macaques with enzootic strains of venezuelan equine encephalitis viruses.. J Infect Dis 2004 Mar 15;189(6):1013-7.
                  pubmed: 14999604doi: 10.1086/382281google scholar: lookup
                15. Johnstone RE, Peters CJ. Alphaviruses. 1995. pp. 843–898.
                16. Smith JF, Davis K, Hart MK, Ludwig GV, McClain DJ, Parker MD, Pratt WD. Viral encephalitides. Textbook of Military Medicine; Medical Aspects of Chemical and Biological Warfare Washington DC: Office of surgeon general; 1997. pp. 561–589.
                17. Blue Book, Sixth Edition, April 2005. US Army Medical Research Institute of Infectious Disease (USAMRIID), Published by USAMRIID, the lead medical research laboratory for the US Biological Defense Research Program
                18. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains.. Nature 1990 Dec 6;348(6301):552-4.
                  pubmed: 2247164doi: 10.1038/348552a0google scholar: lookup
                19. Breitling F, Dübel S, Seehaus T, Klewinghaus I, Little M. A surface expression vector for antibody screening.. Gene 1991 Aug 15;104(2):147-53.
                  pubmed: 1916287doi: 10.1016/0378-1119(91)90244-6google scholar: lookup
                20. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries.. Nature 1991 Aug 15;352(6336):624-8.
                  pubmed: 1907718doi: 10.1038/352624a0google scholar: lookup
                21. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains.. Nucleic Acids Res 1991 Aug 11;19(15):4133-7.
                  pmc: PMC328552pubmed: 1908075doi: 10.1093/nar/19.15.4133google scholar: lookup
                22. Better M, Chang CP, Robinson RR, Horwitz AH. Escherichia coli secretion of an active chimeric antibody fragment.. Science 1988 May 20;240(4855):1041-3.
                  pubmed: 3285471doi: 10.1126/science.3285471google scholar: lookup
                23. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.. Proc Natl Acad Sci U S A 1988 Aug;85(16):5879-83.
                  pmc: PMC281868pubmed: 3045807doi: 10.1073/pnas.85.16.5879google scholar: lookup
                24. Konthur Z, Hust M, Dübel S. Perspectives for systematic in vitro antibody generation.. Gene 2005 Dec 30;364:19-29.
                  pubmed: 16126351doi: 10.1016/j.gene.2005.05.042google scholar: lookup
                25. Hust M, Dübel S, Schirrmann T. Selection of recombinant antibodies from antibody gene libraries.. Methods Mol Biol 2007;408:243-55.
                  pubmed: 18314587doi: 10.1007/978-1-59745-547-3_14google scholar: lookup
                26. van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus AD, Preiser W, Doerr HW, de Kruif J, Goudsmit J. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.. J Virol 2005 Feb;79(3):1635-44.
                  pmc: PMC544131pubmed: 15650189doi: 10.1128/jvi.79.3.1635-1644.2005google scholar: lookup
                27. Rodríguez-Díaz J, Monedero V, Pérez-Martínez G, Buesa J. Single-chain variable fragment (scFv) antibodies against rotavirus NSP4 enterotoxin generated by phage display.. J Virol Methods 2004 Nov;121(2):231-8.
                  pubmed: 15381361doi: 10.1016/j.jviromet.2004.07.002google scholar: lookup
                28. Donà MG, Giorgi C, Accardi L. Characterization of antibodies in single-chain format against the E7 oncoprotein of the human papillomavirus type 16 and their improvement by mutagenesis.. BMC Cancer 2007 Jan 31;7:25.
                  pmc: PMC1797048pubmed: 17266749doi: 10.1186/1471-2407-7-25google scholar: lookup
                29. Velappan N, Martinez JS, Valero R, Chasteen L, Ponce L, Bondu-Hawkins V, Kelly C, Pavlik P, Hjelle B, Bradbury AR. Selection and characterization of scFv antibodies against the Sin Nombre hantavirus nucleocapsid protein.. J Immunol Methods 2007 Apr 10;321(1-2):60-9.
                  pubmed: 17336997doi: 10.1016/j.jim.2007.01.011google scholar: lookup
                30. de Carvalho Nicacio C, Williamson RA, Parren PW, Lundkvist A, Burton DR, Björling E. Neutralizing human Fab fragments against measles virus recovered by phage display.. J Virol 2002 Jan;76(1):251-8.
                  pmc: PMC135717pubmed: 11739690doi: 10.1128/jvi.76.1.251-258.2002google scholar: lookup
                31. Koch J, Liang M, Queitsch I, Kraus AA, Bautz EK. Human recombinant neutralizing antibodies against hantaan virus G2 protein.. Virology 2003 Mar 30;308(1):64-73.
                  pubmed: 12706090doi: 10.1016/s0042-6822(02)00094-6google scholar: lookup
                32. Duan J, Ji X, Feng J, Han W, Zhang P, Cao W, Guo X, Qi C, Yang D, Jin G, Gao G, Yan X. A human neutralizing antibody against a conformational epitope shared by oligomeric SARS S1 protein.. Antivir Ther 2006;11(1):117-23.
                  pubmed: 16518967
                33. Calisher CH, Karabatsos N, Lazuick JS, Monath TP, Wolff KL. Reevaluation of the western equine encephalitis antigenic complex of alphaviruses (family Togaviridae) as determined by neutralization tests.. Am J Trop Med Hyg 1988 Mar;38(2):447-52.
                  pubmed: 2833129doi: 10.4269/ajtmh.1988.38.447google scholar: lookup
                34. Nagata LP, Hu WG, Parker M, Chau D, Rayner GA, Schmaltz FL, Wong JP. Infectivity variation and genetic diversity among strains of Western equine encephalitis virus.. J Gen Virol 2006 Aug;87(Pt 8):2353-2361.
                  pubmed: 16847131doi: 10.1099/vir.0.81815-0google scholar: lookup
                35. Greiser-Wilke IM, Moennig V, Kaaden OR, Shope RE. Detection of alphaviruses in a genus-specific antigen capture enzyme immunoassay using monoclonal antibodies.. J Clin Microbiol 1991 Jan;29(1):131-7.
                  pmc: PMC269716pubmed: 1847149doi: 10.1128/jcm.29.1.131-137.1991google scholar: lookup
                36. Mathews JH, Roehrig JT. Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies.. J Immunol 1982 Dec;129(6):2763-7.
                  pubmed: 6183343
                37. Roehrig JT, Hunt AR, Kinney RM, Mathews JH. In vitro mechanisms of monoclonal antibody neutralization of alphaviruses.. Virology 1988 Jul;165(1):66-73.
                  pubmed: 2455383doi: 10.1016/0042-6822(88)90659-9google scholar: lookup
                38. Hunt AR, Roehrig JT. Localization of a protective epitope on a Venezuelan equine encephalomyelitis (VEE) virus peptide that protects mice from both epizootic and enzootic VEE virus challenge and is immunogenic in horses.. Vaccine 1995 Feb;13(3):281-8.
                  pubmed: 7543231doi: 10.1016/0264-410x(95)93315-zgoogle scholar: lookup
                39. Hunt AR, Frederickson S, Hinkel C, Bowdish KS, Roehrig JT. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus.. J Gen Virol 2006 Sep;87(Pt 9):2467-2476.
                  pubmed: 16894184doi: 10.1099/vir.0.81925-0google scholar: lookup
                40. Roehrig JT, Mathews JH. The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes.. Virology 1985 Apr 30;142(2):347-56.
                  pubmed: 2414905doi: 10.1016/0042-6822(85)90343-5google scholar: lookup
                41. Wang E, Paessler S, Aguilar PV, Smith DR, Coffey LL, Kang W, Pfeffer M, Olson J, Blair PJ, Guevara C, Estrada-Franco J, Weaver SC. A novel, rapid assay for detection and differentiation of serotype-specific antibodies to Venezuelan equine encephalitis complex alphaviruses.. Am J Trop Med Hyg 2005 Jun;72(6):805-10.
                  pubmed: 15964967
                42. Duggan JM, Coates DM, Ulaeto DO. Isolation of single-chain antibody fragments against Venezuelan equine encephalomyelitis virus from two different immune sources.. Viral Immunol 2001;14(3):263-73.
                  pubmed: 11572636doi: 10.1089/088282401753266774google scholar: lookup
                43. Guo YC, Zhou YF, Zhang XE, Zhang ZP, Qiao YM, Bi LJ, Wen JK, Liang MF, Zhang JB. Phage display mediated immuno-PCR.. Nucleic Acids Res 2006 May 8;34(8):e62.
                  pmc: PMC1458518pubmed: 16682441doi: 10.1093/nar/gkl260google scholar: lookup
                44. Spearman C. The method of right and wrong cases (constat stimuli) without Gauss formulae. Brit J Psychol 1908;2:227–242.
                45. Kaerber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol 1931;162:480–483.
                46. Berge TO, Banks IS, Tiggert WD. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells. American Journal of Hygiene 1961;73:209–218.
                47. Frolov IV, Kolykhalov AA, Volchakov VE, Netesov SV, Sandakhchiev LS. [Comparison of the amino acid sequence of structural proteins from attenuated and pathogenic strains of the Venezuelan equine encephalomyelitis virus].. Dokl Akad Nauk SSSR 1991;318(6):1488-91.
                  pubmed: 1914828
                48. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3. New York: Cold Spring Harbor Laboratory Press; 2001.
                49. Hust M, Toleikis L, Dübel S. Antibody phage display. Handbook of therapeutic antibodies Weinheim: Willey-VCH; 2007. pp. 45–68.
                50. Pelat T, Hust M, Laffly E, Condemine F, Bottex C, Vidal D, Lefranc MP, Dübel S, Thullier P. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.. Antimicrob Agents Chemother 2007 Aug;51(8):2758-64.
                  pmc: PMC1932538pubmed: 17517846doi: 10.1128/aac.01528-06google scholar: lookup
                51. Rondot S, Koch J, Breitling F, Dübel S. A helper phage to improve single-chain antibody presentation in phage display.. Nat Biotechnol 2001 Jan;19(1):75-8.
                  pubmed: 11135557doi: 10.1038/83567google scholar: lookup
                52. Hust M, Meysing M, Schirrmann T, Selke M, Meens J, Gerlach GF, Dübel S. Enrichment of open reading frames presented on bacteriophage M13 using hyperphage.. Biotechniques 2006 Sep;41(3):335-42.
                  pubmed: 16989094doi: 10.2144/000112225google scholar: lookup
                53. Soltes G, Hust M, Ng KK, Bansal A, Field J, Stewart DI, Dübel S, Cha S, Wiersma EJ. On the influence of vector design on antibody phage display.. J Biotechnol 2007 Jan 20;127(4):626-37.
                  pmc: PMC1866265pubmed: 16996161doi: 10.1016/j.jbiotec.2006.08.015google scholar: lookup
                54. Retter I, Althaus HH, Münch R, Müller W. VBASE2, an integrative V gene database.. Nucleic Acids Res 2005 Jan 1;33(Database issue):D671-4.
                  pmc: PMC540042pubmed: 15608286doi: 10.1093/nar/gki088google scholar: lookup
                55. Mollova S, Retter I, Müller W. Visualising the immune repertoire. BMC Systems Biology 2007;1:P30.
                56. Kirsch M, Zaman M, Meier D, Dübel S, Hust M. Parameters affecting the display of antibodies on phage.. J Immunol Methods 2005 Jun;301(1-2):173-85.
                  pubmed: 15992816doi: 10.1016/j.jim.2005.04.017google scholar: lookup
                57. Li J, Menzel C, Meier D, Zhang C, Dübel S, Jostock T. A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies.. J Immunol Methods 2007 Jan 10;318(1-2):113-24.
                  pubmed: 17161420doi: 10.1016/j.jim.2006.10.010google scholar: lookup

                Citations

                This article has been cited 38 times.
                1. Tulika T, Ljungars A. Deep Mining of Complex Antibody Phage Pools. Methods Mol Biol 2023;2702:419-431.
                  doi: 10.1007/978-1-0716-3381-6_22pubmed: 37679633google scholar: lookup
                2. Heine PA, Ruschig M, Langreder N, Wenzel EV, Schubert M, Bertoglio F, Hust M. Antibody Selection in Solution Using Magnetic Beads. Methods Mol Biol 2023;2702:261-274.
                  doi: 10.1007/978-1-0716-3381-6_13pubmed: 37679624google scholar: lookup
                3. Steinke S, Roth KDR, Ruschig M, Langreder N, Polten S, Schneider KT, Ballmann R, Russo G, Zilkens KJK, Schubert M, Bertoglio F, Hust M. Antibody Selection via Phage Display in Microtiter Plates. Methods Mol Biol 2023;2702:247-260.
                  doi: 10.1007/978-1-0716-3381-6_12pubmed: 37679623google scholar: lookup
                4. Ruschig M, Heine PA, Fühner V, Zilkens KJK, Steinke S, Schubert M, Bertoglio F, Hust M. Construction of Human Immune and Naive scFv Phage Display Libraries. Methods Mol Biol 2023;2702:15-37.
                  doi: 10.1007/978-1-0716-3381-6_2pubmed: 37679613google scholar: lookup
                5. Maeta S, Nakakido M, Matsuura H, Sakai N, Hirata K, Kuroda D, Fukunaga A, Tsumoto K. Arginine cluster introduction on framework region in anti-lysozyme antibody improved association rate constant by changing conformational diversity of CDR loops. Protein Sci 2023 Sep;32(9):e4745.
                  doi: 10.1002/pro.4745pubmed: 37550885google scholar: lookup
                6. André AS, Moutinho I, Dias JNR, Aires-da-Silva F. In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties. Front Microbiol 2022;13:962124.
                  doi: 10.3389/fmicb.2022.962124pubmed: 36225354google scholar: lookup
                7. Kim AS, Kafai NM, Winkler ES, Gilliland TC Jr, Cottle EL, Earnest JT, Jethva PN, Kaplonek P, Shah AP, Fong RH, Davidson E, Malonis RJ, Quiroz JA, Williamson LE, Vang L, Mack M, Crowe JE Jr, Doranz BJ, Lai JR, Alter G, Gross ML, Klimstra WB, Fremont DH, Diamond MS. Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope. Cell 2021 Aug 19;184(17):4414-4429.e19.
                  doi: 10.1016/j.cell.2021.07.006pubmed: 34416146google scholar: lookup
                8. Roth KDR, Wenzel EV, Ruschig M, Steinke S, Langreder N, Heine PA, Schneider KT, Ballmann R, Fühner V, Kuhn P, Schirrmann T, Frenzel A, Dübel S, Schubert M, Moreira GMSG, Bertoglio F, Russo G, Hust M. Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy. Front Cell Infect Microbiol 2021;11:697876.
                  doi: 10.3389/fcimb.2021.697876pubmed: 34307196google scholar: lookup
                9. Huang R, Kiss MM, Batonick M, Weiner MP, Kay BK. Generating Recombinant Antibodies to Membrane Proteins through Phage Display. Antibodies (Basel) 2016 May 2;5(2).
                  doi: 10.3390/antib5020011pubmed: 31557992google scholar: lookup
                10. Burke CW, Froude JW, Miethe S, Hülseweh B, Hust M, Glass PJ. Human-Like Neutralizing Antibodies Protect Mice from Aerosol Exposure with Western Equine Encephalitis Virus. Viruses 2018 Mar 24;10(4).
                  doi: 10.3390/v10040147pubmed: 29587363google scholar: lookup
                11. Chan SK, Rahumatullah A, Lai JY, Lim TS. Naïve Human Antibody Libraries for Infectious Diseases. Adv Exp Med Biol 2017;1053:35-59.
                  doi: 10.1007/978-3-319-72077-7_3pubmed: 29549634google scholar: lookup
                12. Sadana P, Geyer R, Pezoldt J, Helmsing S, Huehn J, Hust M, Dersch P, Scrima A. The invasin D protein from Yersinia pseudotuberculosis selectively binds the Fab region of host antibodies and affects colonization of the intestine. J Biol Chem 2018 Jun 1;293(22):8672-8690.
                  doi: 10.1074/jbc.RA117.001068pubmed: 29535184google scholar: lookup
                13. Kłopot A, Zakrzewska A, Lecion D, Majewska JM, Harhala MA, Lahutta K, Kaźmierczak Z, Łaczmański Ł, Kłak M, Dąbrowska K. Real-Time qPCR as a Method for Detection of Antibody-Neutralized Phage Particles. Front Microbiol 2017;8:2170.
                  doi: 10.3389/fmicb.2017.02170pubmed: 29163448google scholar: lookup
                14. Unkauf T, Miethe S, Fühner V, Schirrmann T, Frenzel A, Hust M. Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy. Adv Exp Med Biol 2016;917:55-76.
                  doi: 10.1007/978-3-319-32805-8_4pubmed: 27236552google scholar: lookup
                15. Kuhn P, Fühner V, Unkauf T, Moreira GM, Frenzel A, Miethe S, Hust M. Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. Proteomics Clin Appl 2016 Oct;10(9-10):922-948.
                  doi: 10.1002/prca.201600002pubmed: 27198131google scholar: lookup
                16. Avril A, Miethe S, Popoff MR, Mazuet C, Chahboun S, Rasetti-Escargueil C, Sesardic D, Thullier P, Hust M, Pelat T. Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain. BMC Biotechnol 2015 Sep 17;15:86.
                  doi: 10.1186/s12896-015-0206-0pubmed: 26382731google scholar: lookup
                17. Kügler J, Wilke S, Meier D, Tomszak F, Frenzel A, Schirrmann T, Dübel S, Garritsen H, Hock B, Toleikis L, Schütte M, Hust M. Generation and analysis of the improved human HAL9/10 antibody phage display libraries. BMC Biotechnol 2015 Feb 19;15:10.
                  doi: 10.1186/s12896-015-0125-0pubmed: 25888378google scholar: lookup
                18. Fuchs M, Kämpfer S, Helmsing S, Spallek R, Oehlmann W, Prilop W, Frank R, Dübel S, Singh M, Hust M. Novel human recombinant antibodies against Mycobacterium tuberculosis antigen 85B. BMC Biotechnol 2014 Jul 17;14:68.
                  doi: 10.1186/1472-6750-14-68pubmed: 25033887google scholar: lookup
                19. Hülseweh B, Rülker T, Pelat T, Langermann C, Frenzel A, Schirrmann T, Dübel S, Thullier P, Hust M. Human-like antibodies neutralizing Western equine encephalitis virus. MAbs 2014 May-Jun;6(3):718-27.
                  doi: 10.4161/mabs.28170pubmed: 24518197google scholar: lookup
                20. Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, Frenzel A, Schirrmann T, Thullier P, Sesardic D, Hust M. Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs 2014 Mar-Apr;6(2):446-59.
                  doi: 10.4161/mabs.27773pubmed: 24492304google scholar: lookup
                21. Shafagati N, Patanarut A, Luchini A, Lundberg L, Bailey C, Petricoin E 3rd, Liotta L, Narayanan A, Lepene B, Kehn-Hall K. The use of Nanotrap particles for biodefense and emerging infectious disease diagnostics. Pathog Dis 2014 Jul;71(2):164-76.
                  doi: 10.1111/2049-632X.12136pubmed: 24449537google scholar: lookup
                22. Steinwand M, Droste P, Frenzel A, Hust M, Dübel S, Schirrmann T. The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs 2014 Jan-Feb;6(1):204-18.
                  doi: 10.4161/mabs.27227pubmed: 24262918google scholar: lookup
                23. Jäger V, Büssow K, Wagner A, Weber S, Hust M, Frenzel A, Schirrmann T. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol 2013 Jun 26;13:52.
                  doi: 10.1186/1472-6750-13-52pubmed: 23802841google scholar: lookup
                24. Rülker T, Voß L, Thullier P, O' Brien LM, Pelat T, Perkins SD, Langermann C, Schirrmann T, Dübel S, Marschall HJ, Hust M, Hülseweh B. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One 2012;7(5):e37242.
                  doi: 10.1371/journal.pone.0037242pubmed: 22666347google scholar: lookup
                25. Huang JX, Bishop-Hurley SL, Cooper MA. Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother 2012 Sep;56(9):4569-82.
                  doi: 10.1128/AAC.00567-12pubmed: 22664969google scholar: lookup
                26. Froude JW, Stiles B, Pelat T, Thullier P. Antibodies for biodefense. MAbs 2011 Nov-Dec;3(6):517-27.
                  doi: 10.4161/mabs.3.6.17621pubmed: 22123065google scholar: lookup
                27. Chahboun S, Hust M, Liu Y, Pelat T, Miethe S, Helmsing S, Jones RG, Sesardic D, Thullier P. Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol 2011 Nov 23;11:113.
                  doi: 10.1186/1472-6750-11-113pubmed: 22111995google scholar: lookup
                28. Bradbury AR, Sidhu S, Dübel S, McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 2011 Mar;29(3):245-54.
                  doi: 10.1038/nbt.1791pubmed: 21390033google scholar: lookup
                29. Thie H, Toleikis L, Li J, von Wasielewski R, Bastert G, Schirrmann T, Esteves IT, Behrens CK, Fournes B, Fournier N, de Romeuf C, Hust M, Dübel S. Rise and fall of an anti-MUC1 specific antibody. PLoS One 2011 Jan 14;6(1):e15921.
                  doi: 10.1371/journal.pone.0015921pubmed: 21264246google scholar: lookup
                30. Schirrmann T, Meyer T, Schütte M, Frenzel A, Hust M. Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules 2011 Jan 10;16(1):412-26.
                  doi: 10.3390/molecules16010412pubmed: 21221060google scholar: lookup
                31. Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl Trop Dis 2010 Jul 13;4(7):e739.
                  doi: 10.1371/journal.pntd.0000739pubmed: 20644615google scholar: lookup
                32. Ren X, Wang M, Yin J, Li G. Phages harboring specific peptides that recognize the N protein of the porcine reproductive and respiratory syndrome virus distinguish the virus from other viruses. J Clin Microbiol 2010 May;48(5):1875-81.
                  doi: 10.1128/JCM.01707-09pubmed: 20237096google scholar: lookup
                33. Pelat T, Thullier P. Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies. MAbs 2009 Jul-Aug;1(4):377-81.
                  doi: 10.4161/mabs.1.4.8635pubmed: 20068407google scholar: lookup
                34. O'Brien LM, Underwood-Fowler CD, Goodchild SA, Phelps AL, Phillpotts RJ. Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains. Virol J 2009 Nov 19;6:206.
                  doi: 10.1186/1743-422X-6-206pubmed: 19925641google scholar: lookup
                35. Schütte M, Thullier P, Pelat T, Wezler X, Rosenstock P, Hinz D, Kirsch MI, Hasenberg M, Frank R, Schirrmann T, Gunzer M, Hust M, Dübel S. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One 2009 Aug 13;4(8):e6625.
                  doi: 10.1371/journal.pone.0006625pubmed: 19675673google scholar: lookup
                36. Pelat T, Hust M, Hale M, Lefranc MP, Dübel S, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 2009 Jun 30;9:60.
                  doi: 10.1186/1472-6750-9-60pubmed: 19563687google scholar: lookup
                37. de Souza CC, Glória JC, da Silva ERD, de Lima Guerra Corado A, de Alcântara KÁG, Cordeiro IB, de Andrade EV, Mariúba LAM. Single-Stranded Variable Fragment Gene Libraries Built for Phage Display: An Updated Review of Design, Selection and Application. J Microbiol Biotechnol 2024 Oct 24;35:e2407049.
                  doi: 10.4014/jmb.2407.07049pubmed: 39631781google scholar: lookup
                38. Kim SM, Heo HR, Kim CS, Shin HH. Genetically engineered bacteriophages as novel nanomaterials: applications beyond antimicrobial agents. Front Bioeng Biotechnol 2024;12:1319830.
                  doi: 10.3389/fbioe.2024.1319830pubmed: 38725991google scholar: lookup
                Subscribe to our newsletter
                Join 99,658 horse owners like you who receive our email updates on horse health and nutrition.